We hear about MolDx tech assessments and retroactive coverage; here is an example.
Publicly-held Personalis released its 2Q (June 30, 2024) financials as an SEC 10-Q on about August 7, 2024.
They remark,
In January 2024, we announced that we received a final Medicare coverage determination for our NeXT Dx offering, extended retroactively to August 29, 2023. While we estimate that approximately half of new solid tumor cancer cases will be diagnosed in patients covered by Medicare...
https://investors.personalis.com/static-files/1b727c36-7351-4f6f-ab2b-d3a252287e54
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.